Similar to the Gpr43−/− results shown in Fig. 3f, h, propionate treatment resulted in no change in GVHD severity whereas butyrate treatment partially ameliorated GVHD in [WT B6 → Nlrp3−/−] recipients (Fig. 6e, f). The gene discussed is FFAR2; the disease is graft versus host disease.